These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 26219615)

  • 1. New Antiangiogenetic Therapy Beyond Bevacizumab in the Treatment of Advanced Non Small Cell Lung Cancer.
    Sacco PC; Maione P; Rossi A; Sgambato A; Casaluce F; Palazzolo G; Gridelli C
    Curr Pharm Des; 2015; 21(32):4763-72. PubMed ID: 26219615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring the Benefit/Risk Associated with Antiangiogenic Agents for the Treatment of Non-Small Cell Lung Cancer Patients.
    Kurzrock R; Stewart DJ
    Clin Cancer Res; 2017 Mar; 23(5):1137-1148. PubMed ID: 27940520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-Angiogenics: Their Value in Lung Cancer Therapy.
    Janning M; Loges S
    Oncol Res Treat; 2018; 41(4):172-180. PubMed ID: 29631257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting angiogenesis for treatment of NSCLC brain metastases.
    Schettino C; Bareschino MA; Rossi A; Maione P; Sacco PC; Colantuoni G; Rossi E; Gridelli C
    Curr Cancer Drug Targets; 2012 Mar; 12(3):289-99. PubMed ID: 22229249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Role of the Antiangiogenetic Ramucirumab in the Treatment of Advanced Non Small Cell Lung Cancer.
    Maione P; Sgambato A; Casaluce F; Sacco PC; Santabarbara G; Rossi A; Gridelli C
    Curr Med Chem; 2017; 24(1):3-13. PubMed ID: 27855622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bevacizumab in the treatment of nonsquamous non-small cell lung cancer: clinical trial evidence and experience.
    Greillier L; Tomasini P; Barlesi F
    Ther Adv Respir Dis; 2016 Oct; 10(5):485-91. PubMed ID: 27340254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-EGFR and antiangiogenic monoclonal antibodies in metastatic non-small-cell lung cancer.
    Losanno T; Rossi A; Maione P; Napolitano A; Gridelli C
    Expert Opin Biol Ther; 2016 Jun; 16(6):747-58. PubMed ID: 26950292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the VEGF pathway: antiangiogenic strategies in the treatment of non-small cell lung cancer.
    Aita M; Fasola G; Defferrari C; Brianti A; Bello MG; Follador A; Sinaccio G; Pronzato P; Grossi F
    Crit Rev Oncol Hematol; 2008 Dec; 68(3):183-96. PubMed ID: 18606548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiogenesis inhibition in the treatment of lung cancer.
    Vokes E; Herbst R; Sandler A
    Clin Adv Hematol Oncol; 2006 Nov; 4(11 Suppl 23):1-10; quiz 11-2. PubMed ID: 17143257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Current progression of bevacizumab in advanced non-small cell lung cancer].
    Chu TQ; Chen JH; Han BH
    Zhonghua Zhong Liu Za Zhi; 2018 Oct; 40(10):793-800. PubMed ID: 30392346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel angiogenesis inhibitors in nonsmall cell lung cancer.
    Reinmuth N; Heigener D; Reck M
    Curr Opin Oncol; 2015 Mar; 27(2):79-86. PubMed ID: 25602682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting angiogenesis in squamous non-small cell lung cancer.
    Piperdi B; Merla A; Perez-Soler R
    Drugs; 2014 Mar; 74(4):403-13. PubMed ID: 24578213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New antiangiogenetic agents and non-small cell lung cancer.
    Gridelli C; Rossi A; Maione P
    Crit Rev Oncol Hematol; 2006 Oct; 60(1):76-86. PubMed ID: 16843002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging antiangiogenic therapies for non-small-cell lung cancer.
    Blakely C; Jahan T
    Expert Rev Anticancer Ther; 2011 Oct; 11(10):1607-18. PubMed ID: 21999134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nintedanib (BIBF 1120) blocks the tumor promoting signals of lung fibroblast soluble microenvironment.
    Epstein Shochet G; Israeli-Shani L; Koslow M; Shitrit D
    Lung Cancer; 2016 Jun; 96():7-14. PubMed ID: 27133742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. International Experts Panel Meeting of the Italian Association of Thoracic Oncology on Antiangiogenetic Drugs for Non-Small Cell Lung Cancer: Realities and Hopes.
    de Marinis F; Bria E; Ciardiello F; Crinò L; Douillard JY; Griesinger F; Lambrechts D; Perol M; Ramalingam SS; Smit EF; Gridelli C
    J Thorac Oncol; 2016 Jul; 11(7):1153-69. PubMed ID: 27063293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of anti-angiogenesis in non-small-cell lung cancer: an update.
    Villaruz LC; Socinski MA
    Curr Oncol Rep; 2015 Jun; 17(6):26. PubMed ID: 25947099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New options for integrating antiangiogenic therapy and platinum-based first-line chemotherapy for advanced non-small-cell lung cancer.
    Manegold C
    Clin Lung Cancer; 2008; 9 Suppl 3():S100-8. PubMed ID: 19419923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic options targeting angiogenesis in nonsmall cell lung cancer.
    Crinò L; Metro G
    Eur Respir Rev; 2014 Mar; 23(131):79-91. PubMed ID: 24591665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiogenesis in the treatment of non-small cell lung cancer.
    Horn L; Sandler AB
    Proc Am Thorac Soc; 2009 Apr; 6(2):206-17. PubMed ID: 19349490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.